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Introduction. The valosin-containing protein (VCP) regulates several distinct cellular processes. Consistent with this, VCP
mutations manifest variable clinical phenotypes among and within families and are a diagnostic challenge. Methods. A 60-year-
old man who played ice hockey into his 50’s was evaluated by electrodiagnostics, muscle biopsy, and molecular genetics. Results.
With long-standing pes cavus and toe walking, our patient developed progressive weakness, cramps, memory loss, and paresthesias
at age 52. An axonal sensorimotor neuropathy was found upon repeated testing at age 58. Neuropathic histopathology was present
in the quadriceps, and exome sequencing revealed the VCPmutation c.290 C>T, p.Gly97Glu. Conclusions. Our patient reflects the
clinical heterogeneity of VCPmutations, as his neurological localization is a spectrum between a lower motor neuron disorder and
a hereditary axonal peripheral neuropathy such as CMT2. Our case demonstrates a rare manifestation of the c.290 C>T, pGly97Glu
VCPmutation.
1. Introduction
The valosin-containing protein (VCP) has been demon-
strated to play a critical role in the maintenance of protein
homeostasis through the regulation of protein degradation
pathways [1]. Mutations in the gene encoding VCP lead to
disruption of autophagy and have been shown to manifest
within families as a phenotypically heterogeneous group of
presentations including hereditary inclusion body myopathy
(IBM), Paget’s disease of the bone (PDB), and frontotemporal
dementia (FTD), which are known collectively as IBMPFD
[2]. More recently, mutations in VCP have been implicated
as having a role in familial amyotrophic lateral sclerosis
(ALS) [3]. Although there is variability in the phenotypic
manifestations of VCP mutations within families, VCP-
related disease is inherited in an autosomal dominantmanner
[2, 3]. Attempts at determining genotype-phenotype corre-
lations for mutations in the VCP gene have been unsuc-
cessful, though analysis of the two most common mutations
(p.Arg155Cys and p.Arg155His) showed a significant varia-
tion in survival between the groups, suggesting that mutation
variants may hold clinical relevance for patients [4].
We report a case of a patient presenting for evaluation
of progressive lower extremity weakness and paresthesias in
the context of family history of ALS, dementia, and PDB.
Exome sequencing revealed a previously reported c.290 C>T,
p.Gly97Glu mutation in VCP; our patient’s phenotype is
different from the previously reported case of IBMPFD [5].
Hindawi Publishing Corporation
Case Reports in Genetics
Volume 2015, Article ID 239167, 5 pages
http://dx.doi.org/10.1155/2015/239167
2 Case Reports in Genetics
(a)
(b)
Figure 1: Evidence of pes cavus and hammer toes in our patient.
The clinical presentation along a continuum from an axonal
sensorimotor polyneuropathy to a lower motor neuronopa-
thy in this patient expands the known clinical phenotypes of
VCP-related disease.
2. Case Report
The proband is a 60-year-old man of Dutch and Italian
descent who was the product of a normal pregnancy and
delivery. Although he was a toe walker with high arches
and hammertoes, he reached his developmental milestones
(including walking) on time. In grade school, he kept up with
his peers but was always the slowest runner. He rode a bicycle
and played ice hockey until age 52 when he sprained his left
ankle and began noticing progressive left greater than right
leg weakness. At age 55, he began noticing paresthesias and
numbness in his toes with the left side worse than the right.
By age 57, holding his trumpetwas difficult, although he could
still play it well. Three years later, he was unable to climb
stairs, had multiple falls, and began to use a walker. He later
developed cramps in his hands and trouble with fine finger
dexterity. Additionally, he noticedmemory andword-finding
difficulties.
Upon neurological examination in our clinic at age 60, he
presented with bilateral scapular winging, lumbar lordosis,
pes cavus, hammer toes, and tight heel cords (Figure 1).
Strength exam (MRC scale) demonstrated proximal upper
and proximal/distal lower extremity weakness. There was
weakness in trapezius (R/L) 3/3 with scapular winging as well
as weakness in the iliopsoas 4+/4+, quadriceps 4+/5, knee
flexion 4/4, foot dorsiflexion 1/4, and foot plantar flexion
4+/5. Vibratory sense and pinprick were decreased distally in
the lower extremities. Deep tendon reflexes were depressed
throughout the upper and lower extremitieswith absent ankle
jerks and downgoing toes. There was no tremor. Cerebellar
testing was normal. Gait was wide-based with bilateral step-
page; he was unable to walk 25 feet independently due to the
weakness in his lower extremities. Speech and language were
intact. Cranial nerves were normal including facial strength,
facial sensation, and tongue strength. No fasciculations were
noted on exam. Of note, he did not develop any upper
motor neuron signs over the years including hyperreflexia,
dysphagia, dysarthria, or dyspnea.
Laboratory testing included creatine kinase level of
930 u/L (normal 40–200 u/L) and a normal alkaline phos-
phatase level.
2.1. Electrodiagnostic Exam. Although the abnormalities on
the EMGremained constant, nerve conduction studies (NCS)
changed over time.
At age 56, needle EMG revealed fibrillations, positive
sharp waves, fasciculations, and large amplitude motor unit
potentials with reduced recruitment in bilateral tibialis ante-
rior, bilateral vastus lateralis, left gastrocnemius, left deltoid,
left first dorsal interosseous, and left thoracic paraspinal
musculature. Nerve conduction studies of the left ulnar, sural,
and tibial nerves were normal. At this time, the impression
was a lower motor neuron syndrome.
At age 58, although the EMG remained the same, sensory
and motor nerve conduction studies were now abnormal.
The leftmedian, ulnar, and peroneal motor nerve conduction
velocities were normal. Compound muscle action potentials
(CMAPs) of the left median, ulnar, and peroneal nerves were
normal. Sensory nerve action potentials (SNAPs) of the left
median, radial, and superficial peroneal nerves were normal;
right ulnar SNAP had reduced amplitude (13 uV). The left
sural and superficial peroneal sensory responses were absent;
right sural sensory responses had reduced amplitude (4 uV).
Left median and ulnar distal motor latencies were prolonged
(5.5ms and 4.2ms, resp.); left median sensory distal latency
was mildly prolonged at 4.0ms. At this time, the impression
was an axonal sensorimotor neuropathy.
The axonal sensorimotor neuropathy was worked up for
acquired causes. Laboratory testing included normal thyroid
stimulating hormone, serum protein electrophoresis, serum
immunofixation, vitamin B-12, and fasting glucose.
2.2. Muscle Biopsy. Muscle biopsy of the quadriceps at age
60 revealed chronic, active neurogenic atrophy. Paraffin
and frozen H&E sections, NADH, and trichrome staining
revealed skeletal muscle with moderate variation in fiber size
due to the presence of angulated, atrophic fibers in small
groups (Figure 2(a)). Immunoperoxidase stains for slow and
fast myosin heavy chains revealed small fiber type groups
(Figures 2(b) and 2(c)). Rare targetoid fibers were seen (not
shown here). Some muscle fascicles had end stage muscle
pathology (Figure 2(d)), likely the result of longstanding
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Figure 2: Muscle biopsy of the quadriceps revealed chronic active neurogenic atrophy ((a), H&E). Fiber type grouping is seen in
immunoperoxidase staining for both slow myosin (b) and fast myosin (c). Some muscle fascicles are much more severely affected and show
features of end stage muscle (d). Scale bar = 100𝜇m in panels (a) and (d); 150𝜇m in panels (b) and (c).
neuropathic disease. No inflammation, myonecrosis, regen-
eration, endomysial fibrosis, inclusion bodies, rimmed vac-
uoles, or ragged-red fibers were identified. All fibers stained
positively for cytochrome C oxidase.
2.3. Neuropsychological Testing. Neuropsychological testing
revealed only mild impairments as he was noted to have
high average to superior baseline functioning. He had only
mild weakness in speed of information processing, problem
solving, fine motor dexterity, speed in visual motor sequenc-
ing, rapid cognitive shifting, verbal memory, and short-term
memory for simple geometric designs. He had an otherwise
normal performance in all other areas (verbal, nonverbal
intellectual skills, single word reading, and language). He was
diagnosed with cognitive deficits, not otherwise specified.
2.4. Family History. Further investigation into the patient’s
family history disclosed his father’s diagnoses of ALS, demen-
tia, and PDB (Figure 3(a)). Muscle biopsy results from the
father are not available. One sister had flat, narrow feet. The
patient’s teenage daughter has high arches and was a toe
walker as a child; she has not had a neurological evaluation
and further evaluation has been declined at this time. His
other teenage daughter is currently asymptomatic. There is
no family history of IBM.
2.5. Genetic Testing. Exome sequencing was performed and
revealed the VCP mutation c.290 C>T, p.Gly97Glu, G97E.
This same mutation resulting in the same amino acid substi-
tution has been reported in five family members with PDB.
All five affected individuals had varying degrees of muscle
weakness diagnosed as inclusion body myopathy, and none
have FTD [5].
3. Discussion
Phenotypic variability is a hallmark of VCP-related disease.
VCP is a member of the type II AAA+ ATPase family
mapped to 9p13.3 that is ubiquitously expressed at high levels
and exerts an influence on a variety of cellular activities
including cell cycle progression, DNA damage repair, the
ubiquitin-proteasome system, and autophagic processes [7–
9]. This variation in physiological activity allows for an
equally impressive range of pathological manifestations to
arise from mutations in the VCP gene, including IBM, PDB,
FTD, and ALS [10]. We believe the VCP mutation c.290
C>T, p.Gly97Glu, G97E mutation is pathogenic because the
mutation in our patient shows increased ATPase activity,
similar to other VCPmutations (Figure 3(b)).
Our patient’s presentation is not straightforward clin-
ically. It is not simply a hereditary axonal sensorimotor
polyneuropathy (given the asymmetry and bilateral scapular
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Figure 3: (a) Family Pedigree. Squares indicate men; circles, women; diagonal lines, deceased; black, VCP mutation. An arrow indicates the
proband. (b) ATPase activity data that shows that the G97E (Gly97Glu mutation) has increased ATPase activity similar to other mutants.The
detailed method was described previously [6]. Purified human p97 proteins (25 nMmonomer final concentration) were used in Assay Buffer
(50mM Tris pH 7.4, 20mMMgCl
2
, 1 mM EDTA, and 0.5mM TCEP) containing 0.01% Triton X-100 and 200 𝜇M ATP. ATPase activity was
determined by addition of Biomol Green Reagent (Enzo Life Sciences). Absorbance at 635 nm was measured after 4min on the Synergy Neo
Microplate Reader (BioTek).
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Figure 4: Spectrum of phenotypic manifestations seen in our patient with a VCPmutation.
winging), a purely lower motor neuron syndrome (given
the bilateral scapular winging and sensory nerve conduction
abnormality) nor a myopathy (despite elevated CK and
scapular winging, there were no myopathic features on
quadriceps muscle biopsy). We propose that our patient
presents along a spectrumof a lowermotor neuron syndrome
and axonal neuropathy (Figure 4). The difficulty in diagnos-
ing a VCP-related condition is due to this extreme hetero-
geneity in clinical presentations. A recent study demonstrates
that a VCP mutation can result in CMT 2 further validating
the phenotypic variability seen in patients with a VCP
mutation [11]. Of note, exome sequencing was negative for
other genetic variants that are known to cause CMT and
a lower motor neuron disease phenotype; this included the
HSPB, BSCL2, GARS, DCTN1, SLC5A7, FBX038, IGHMBP2,
ATP7A, and SETX genes.
Of those individuals reported withVCPmutations, 87.7%
presentedwith IBM, 45%with PDB, and 37.7%with FTD [12].
VCP mutations are also estimated to be the cause of 1-2%
of familial ALS cases [3]. Further complicating this clinical
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scenario is the incomplete penetrance of phenotypes of IBM,
PDB, and FTD as well as the variability in presentation
for VCP-related ALS [12, 13]. The Gly97Glu mutation was
previously reported in both affected and unaffectedmembers
of one family, suggesting that the mutation may not be fully
penetrant [5].VCPmutations have also been demonstrated to
manifest with variable upper motor neuron signs or bulbar
findings. EMG results can be neuropathic or myopathic,
withmany displayingmixedmorphology [13]. Other features
have been observed less frequently in VCP disease, including
dilated cardiomyopathy, cataracts, and axonal sensorimotor
polyneuropathy [10].
Because of the variability in clinical presentations, the
family history is critical. Mutations in VCP are transmitted
in an autosomal dominant fashion. Obtaining a pedigree that
includes IBM, PDB, FTD, or ALS throughout multiple family
members may lead to the consideration of VCP sequencing
as a diagnostic step. Furthermore, repeated electrodiagnostic
testing can be critical to evaluate the progression of the
disease. Our case demonstrates how the electrodiagnostic
testing changed over the years from the initial electrodiagnos-
tic diagnosis of a lower motor neuron syndrome to the later
diagnosis ofmotor neuron disease plus a sensorimotor axonal
neuropathy. Although the neuropathy could be a manifesta-
tion of CMT 2 given his long-standing toe walking and pes
cavus, the appearance of the neuropathy on electrodiagnostic
testing was late. Basic testing for acquired neuropathies was
unrevealing, and thus the electrodiagnostic changes could
possibly reflect a late onset hereditary neuropathy like CMT
2.
Here we present a case with variable phenotypic manifes-
tations ranging from an axonal sensorimotor polyneuropathy
to a lower motor neuron syndrome or even a myopathy all
arising from a mutation in the gene encoding VCP. This
novel presentation further expands the clinical phenotype
associated with VCPmutations and suggests that sequencing
for this gene should be considered for any patients presenting
with these symptoms who have family history positive for
IBM, PDB, FTD, or ALS.
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